Product image of Linagliptin Viatris (Linagliptin) supplied by GNH India

Linagliptin Viatris

Active Ingredient:
Linagliptin
Origin:
EU

Linagliptin Viatris (Linagliptin)

Linagliptin, the active ingredient in Linagliptin Viatris, is a dipeptidyl peptidase‑4 (DPP‑4) inhibitor presented as an oral tablet for oral use. It is employed to improve blood glucose control in adults with type 2 diabetes mellitus and may be used as part of a comprehensive treatment plan.

GNH India supplies Linagliptin Viatris as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide with a focus on quality assurance, regulatory compliance and reliable global logistics. Our network ensures timely delivery and support for healthcare providers across diverse markets. We adhere to stringent Good Distribution Practice standards to maintain product integrity.

Manufacturer / TM Owner

Viatris Limited

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Linagliptin is a DPP‑4 inhibitor used to manage hyperglycaemia in type 2 diabetes.

  • Type 2 diabetes mellitus (monotherapy): lowers fasting and post‑prandial glucose when added to diet and exercise.
  • Type 2 diabetes mellitus (combination therapy): used with metformin, sulfonylureas or insulin to improve overall glycaemic control.
  • Type 2 diabetes mellitus (adjunct therapy): enhances insulin secretion and reduces glucagon release as part of a comprehensive treatment regimen.

How It Works

  • Linagliptin binds reversibly to the active site of the dipeptidyl peptidase‑4 (DPP‑4) enzyme, preventing the degradation of the incretin hormones glucagon‑like peptide‑1 (GLP‑1) and glucose‑dependent insulinotropic polypeptide (GIP). By preserving these hormones, the drug increases glucose‑dependent insulin secretion, suppresses inappropriate glucagon release, and slows gastric emptying, thereby improving post‑prandial and fasting blood glucose levels.

Side Effects

Linagliptin may be associated with several adverse reactions, ranging from mild to serious.

Common Side Effects

  • Upper respiratory tract infection: nasopharyngitis, sinusitis or cough.
  • Headache: mild to moderate intensity.
  • Gastrointestinal discomfort: nausea, abdominal pain or dyspepsia.

Serious or Rare Side Effects

  • Pancreatitis: severe abdominal pain with vomiting.
  • Severe hypersensitivity: rash, angioedema or anaphylaxis.
  • Hepatic enzyme elevation: significant increase in ALT/AST.

Precautions & Warnings

Before prescribing Linagliptin, clinicians should consider several safety aspects and patient-specific factors.

  • Renal impairment: dose adjustment is not required, but monitor renal function regularly.
  • Hepatic disease: use with caution and assess liver enzymes periodically.
  • Cardiovascular risk: evaluate for heart failure history, although no direct contraindication.
  • Concomitant medications: review for potential drug interactions, especially with strong CYP3A4 inhibitors.
  • Pregnancy and lactation: avoid use due to insufficient safety data.
  • Store at ambient temperature: keep below 25 °C, protect from moisture and light in the original packaging.

Avoid Interactions

Linagliptin can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid)

  • Strong CYP3A4 inhibitors (e.g., ketoconazole): may increase linagliptin exposure.
  • Combined use with other DPP‑4 inhibitors: additive effect on glucose lowering, risk of hypoglycaemia.

Moderate Interactions (Monitor Closely)

  • Diuretics (e.g., thiazides): may enhance risk of dehydration and renal effects.
  • Insulin or sulfonylureas: increased hypoglycaemia potential; dose adjustments may be needed.
  • Rifampicin: may reduce linagliptin plasma levels, decreasing efficacy.

Frequently Asked Questions

Linagliptin Viatris is prescribed to improve blood glucose control in adults with type 2 diabetes mellitus. It is used as monotherapy or in combination with other antidiabetic agents when diet and exercise alone are insufficient to achieve target glycaemic levels.

Linagliptin inhibits the dipeptidyl peptidase‑4 (DPP‑4) enzyme, which normally degrades the incretin hormones GLP‑1 and GIP. By blocking DPP‑4, linagliptin prolongs the action of these hormones, leading to increased insulin secretion, reduced glucagon release, and better regulation of blood glucose after meals.

The appropriate dose is determined by the prescribing healthcare professional based on the individual’s clinical condition, renal function, and concomitant therapies. Linagliptin is typically administered once daily, but the exact strength and regimen are set by the prescriber.

Safety data for linagliptin during pregnancy and lactation are limited. Current guidelines advise avoiding its use in pregnant or nursing women unless the potential benefit justifies the potential risk, and the decision should be made by a qualified clinician.

To place an enquiry, visit the product page at gnhindia.com, enter the required quantity, and submit the request. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Linagliptin belongs to the DPP‑4 inhibitor class, which offers glucose‑dependent insulin secretion without causing weight gain, unlike some sulfonylureas or insulin. Compared with SGLT2 inhibitors, it has a lower risk of genital infections but does not provide the same cardiovascular benefits observed with certain SGLT2 agents.

Linagliptin tablets should be stored at ambient temperature, preferably below 25 °C, in the original blister pack or container. Protect the product from moisture, direct sunlight and excessive heat to maintain its stability throughout its shelf life.

Linagliptin is taken orally, usually once a day, with or without food. Patients should swallow the tablet whole with water and follow the dosing schedule prescribed by their healthcare provider.

Serious adverse events, although rare, include acute pancreatitis, severe hypersensitivity reactions such as anaphylaxis, and significant elevations in liver enzymes. Patients should seek immediate medical attention if they experience persistent abdominal pain, rash, swelling, or signs of liver dysfunction.

Linagliptin is contraindicated in patients with a known hypersensitivity to linagliptin or any component of the formulation. Caution is also advised for individuals with a history of pancreatitis, severe hepatic impairment, or those taking other DPP‑4 inhibitors.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Linagliptin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT